Compare BSAC & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | ICLR |
|---|---|---|
| Founded | 1977 | 1990 |
| Country | Chile | Ireland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 13.1B |
| IPO Year | 2002 | 2001 |
| Metric | BSAC | ICLR |
|---|---|---|
| Price | $32.31 | $203.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 18 |
| Target Price | $34.59 | ★ $231.29 |
| AVG Volume (30 Days) | 415.5K | ★ 1.2M |
| Earning Date | 10-30-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.49 | N/A |
| Revenue Next Year | $8.89 | $4.60 |
| P/E Ratio | $14.40 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.65 | $66.57 |
| 52 Week High | $37.72 | $219.04 |
| Indicator | BSAC | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 62.84 |
| Support Level | $31.41 | $157.92 |
| Resistance Level | $33.04 | $219.04 |
| Average True Range (ATR) | 0.83 | 8.28 |
| MACD | 0.15 | 0.41 |
| Stochastic Oscillator | 70.18 | 62.59 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country, with around 25% of the market, and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.